Sponsored by WAVE Life Sciences.
WVE-HDSNP2-002 was discontinued on March 29, 2021. For more information please click here.
WVE-HDSNP2-002 is an open-label extension (OLE) study to evaluate the safety, tolerability, PK, PD, and clinical effects of WVE-120102 in adult patients with early manifest HD who carry a targeted single nucleotide polymorphism, rs362331 (SNP2). To participate in the study, patients must have completed the Phase 1b/2a clinical study WVE-HDSNP2-001.
Status
Study Closed – Not Recruiting
Formal Name
A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients With Huntington’s Disease
Study Type
Interventional (Clinical Trial)
Purpose
WVE-HDSNP2-002 is an open-label extension (OLE) study to evaluate the safety, tolerability, PK, PD, and clinical effects of WVE-120102 in adult patients with early manifest HD who carry a targeted single nucleotide polymorphism, rs362331 (SNP2). To participate in the study, patients must have completed the Phase 1b/2a clinical study WVE-HDSNP2-001.
Canadian Locations:
Edmonton, AB
Location: University of Alberta
Edmonton, Alberta, Canada, T6G 2B7
Status: By invitation only
Toronto, ON
Location: Centre For Movement Disorders
Toronto, Ontario, Canada, M3B 2S7
Status: By invitation only
Montréal, QC
Location: Centre Hospitalier de l’Universite de Montreal
Montreal, Quebec, Canada, H2X019
Status: By invitation only
Ages Eligible for Study: Child, Adult, Older Adult
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria
- Patient successfully completed the Phase 1b/2a study with WVE-120101, WVE-HDSNP1-001.
Exclusion Criteria (eligibility that would exclude you from this study)
- Received an investigational drug other than WVE-120101, including an investigational oligonucleotide, within the past 1 year or 5 half-lives of the drug, whichever is longer.
- Inability to undergo brain MRI (with or without sedation).
- Clinically significant medical finding on the physical examination other than HD that, in the judgment of the Investigator, will make the patient unsuitable for participation in and/or completion of the study procedures.
Source
For more detailed information on this study and others and for the most recent updates, please go to clinicaltrials.gov. ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.